Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy.

Experimental dermatology - 1 Apr 2009

Pincelli Carlo, Pignatti Marco, Borroni Riccardo G

Abstract excerpt

A significant proportion of patients with skin disease do not respond to treatment and adverse drug reactions are a common problem. Genetic factors are important determinants for both drug efficacy and toxicity. The fields of pharmacogenetics and pharmacogenomics examine inter-individual variations in the DNA sequence that are related to drug efficacy and toxicity. Here, we present pharmacogenomic data relevant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug-Related Side Effects and Adverse Reactions
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Skin Diseases

Share to Skin Neoplasms

Share to Treatment Outcome

Source

Identifiers

PMID: 19348000
DOI: 10.1111/j.1600-0625.2009.00852.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy.PMID 19348000Read ↗

Pharmacogenetics in clinical dermatology.Semantic proximity Read ↗

[Pharmacogenomics in dermatology].Semantic proximity Read ↗

Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.Semantic proximity Read ↗

Pharmacogenetic markers of severe cutaneous adverse drug reactions.Semantic proximity Read ↗

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationSemantic proximity Read ↗

The emerging era of pharmacogenomics: current successes, future potential, and challenges.Semantic proximity Read ↗

Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation.Semantic proximity Read ↗

Pharmacogenomics of adverse drug reactions: implementing personalized medicine.Semantic proximity Read ↗

Drug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via PharmacogenomicsSemantic proximity Read ↗

The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of PsoriasisSemantic proximity Read ↗

Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.Semantic proximity Read ↗

Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.